Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | PTGFR | P43088 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
| ▸ | SELP | P16109 | 6/20 | 0.36 |
| ▸ | SELL | P14151 | 5/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374097 | 1.00 | GPR84 (0.42) | GPR84TLR4DAGLATBXA2RPTGFR | |
| SCHEMBL17294503 | 1.00 | GPR84 (0.42) | GPR84TLR4DAGLATBXA2RPTGFR | |
| SCHEMBL3781567 | 1.00 | GPR84 (0.42) | GPR84TLR4DAGLATBXA2RPTGFR | |
| SCHEMBL14332067 | 1.00 | GPR84 (0.42) | GPR84TLR4DAGLATBXA2RPTGFR | |
| SCHEMBL8013415 | 1.00 | GPR84 (0.42) | GPR84TLR4DAGLATBXA2RPTGFR | |
| SCHEMBL10534787 | 1.00 | GPR84 (0.42) | GPR84TLR4DAGLATBXA2RPTGFR | |
| SCHEMBL17001438 | 0.89 | TLR4 (0.34) | GPR84TLR4TBXA2RPTGFRPTGER2 | |
| SCHEMBL5055853 | 0.88 | SELL (0.41) | GPR84TLR4SELPSELL | |
| SCHEMBL8026363 | 0.88 | SELL (0.41) | GPR84TLR4SELPSELL | |
| SCHEMBL9129668 | 0.83 | GPR84 (0.33) | GPR84DAGLATBXA2RPTGFRPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108587995-B | Cells and methods for producing rhamnolipids | 赢创运营有限公司 | 2022-04-01 | — | — | CN | claimed |
| EP-3418388-B1 | CELLS AND METHOD FOR THE PREPARATION OF RHAMNOLIPIDS | EVONIK OPERATIONS GMBH (DE) | 2020-10-28 | — | — | EP | claimed |
| EP-2598646-B1 | CELLS AND METHOD FOR PRODUCING RHAMNOLIPIDS | EVONIK DEGUSSA GMBH (DE) | 2018-11-07 | — | — | EP | claimed |
| US-20130130319-A1 | CELLS AND METHODS FOR PRODUCING RHAMNOLIPIDS | EVONIK GOLDSCHMIDT GMBH (DE) | 2013-05-23 | — | — | US | claimed |
| US-20240002813-A1 | RHAMNOLIPID-PRODUCING CELL HAVING REDUCED GLUCOSE DEHYDROGENASE ACTIVITY | EVONIK OPERATIONS GMBH (DE) | 2024-01-04 | — | — | US | disclosed |
| US-11685905-B2 | Rhamnolipid-producing cell having reduced glucose dehydrogenase activity | EVONIK OPERATIONS GMBH (DE) | 2023-06-27 | — | — | US | disclosed |
| CN-108587995-B | Cells and methods for producing rhamnolipids | 赢创运营有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20190271020-A1 | RHAMNOLIPID-PRODUCING CELL HAVING REDUCED GLUCOSE DEHYDROGENASE ACTIVITY | EVONIK DEGUSSA GMBH (DE) | 2019-09-05 | — | — | US | disclosed |
| EP-3529259-A1 | RHAMNOLIPID-PRODUCING CELL HAVING REDUCED GLUCOSE DEHYDROGENASE ACTIVITY | Evonik Degussa GmbH (DE) | 2019-08-28 | — | — | EP | disclosed |
| EP-3529258-A1 | CELLS AND METHOD FOR PRODUCING RHAMNOLIPIDS USING ALTERNATIVE GLUCOSE TRANSPORTERS | Evonik Degussa GmbH (DE) | 2019-08-28 | — | — | EP | disclosed |
| US-20190233856-A1 | CELLS AND METHOD FOR PRODUCING RHAMNOLIPIDS USING ALTERNATIVE GLUCOSE TRANSPORTERS | EVONIK DEGUSSA GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-10174353-B2 | Methods of producing rhamnolipids | EVONIK DEGUSSA GMBH (DE) | 2019-01-08 | — | — | US | disclosed |
| EP-3259363-A1 | RHAMNOLIPID SYNTHESIS | Evonik Degussa GmbH (DE) | 2017-12-27 | — | — | EP | disclosed |
| US-20170096695-A1 | Methods of Producing Rhamnolipids | EVONIK OPERATIONS GMBH (DE) | 2017-04-06 | — | — | US | disclosed |
| US-9580720-B2 | Cells and methods for producing rhamnolipids | EVONIK DEGUSSA GMBH (DE) | 2017-02-28 | — | — | US | disclosed |
| WO-2016131801-A1 | RHAMNOLIPID SYNTHESIS | EVONIK DEGUSSA GMBH (DE) | 2016-08-25 | — | — | WO | disclosed |
| EP-2949214-A1 | Methods of producing rhamnolipids | Evonik Degussa GmbH (DE) | 2015-12-02 | — | — | EP | disclosed |
| US-20150247151-A1 | CELLS AND METHODS FOR PRODUCING RHAMNOLIPIDS | EVONIK OPERATIONS GMBH (DE) | 2015-09-03 | — | — | US | disclosed |
| US-9005928-B2 | Cells and methods for producing rhamnolipids | EVONIK DEGUSSA GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20130130319-A1 | CELLS AND METHODS FOR PRODUCING RHAMNOLIPIDS | EVONIK GOLDSCHMIDT GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233856-A1 | CELLS AND METHOD FOR PRODUCING RHAMNOLIPIDS USING ALTERNATIVE GLUCOSE TRANSPORTERS | SLC2A1, SLC2A2, SLC2A4 | GPR84 1127/4885TLR4 3130/4885DAGLA 851/4885 |
| US-10174353-B2 | Methods of producing rhamnolipids | LRAT, LCT, RCE1 | GPR84 1763/4885TLR4 3884/4885DAGLA 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.